A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

Novo Nordisk stock slumped early Monday as the drugmaker was facing a hit to revenue from several different directions. This ...

Lilly's study showed that more patients treated with Zepbound had reductions in body weight of at least 10%, 15%, 20%, and 25% than those treated with Wegovy, while they also achieved a greater ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.